Vascular endothelial growth factor (VEGF) is one of the most important inducers of angiogenesis, therefore blocking angiogenesis has led to great promise in the treatment of various cancers and inflammatory diseases. VEGF, expressed in response to soluble mediators such as cytokines and growth factors, is important in the physiological development of blood vessels as well as development of vessels in tumors. In cancer patients VEGF levels are increased, and the expression of VEGF is associated with poor prognosis in diseases. VEGF is a mediator of angiogenesis and inflammation which are closely integrated processes in a number of physiological and pathological conditions including obesity, psoriasis, autoimmune diseases and tumor. Mast cells can be activated by anti-IgE to release potent mediators of inflammation and can also respond to bacterial or viral antigens, cytokines, growth factors and hormones, leading to differential release of distinct mediators without degranulation. Substance P strongly induces VEGF in mast cells, and IL-33 contributes to the stimulation and release of VEGF in human mast cells in a dose-dependent manner and acts synergistically in combination with Substance P. Here we report a strong link between VEGF and mast cells and we depict their role in inflammation and immunity.
BrideauGMäkinenMJElamaaHTuHNilssonGAlitaloKPihlajaniemiTHeljasvaaraR. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res2007; 67(24): 11528–35.
2.
CarmelietPde AlmodovarC Ruiz. VEGF ligands and receptors: Implications in neurodevelopment and neurodegeneration. Cell Mol Life Sci2013; 70(10):1763–78.
3.
LichtTKeshetE. Delineating multiple functions of VEGF-A in the adult brain. Cell Mol Life Sci2013;70(10):1727–37.
4.
KoltowskaKBettermanKLHarveyNLHoganBM. Getting out and about: The emergence and morphogenesis of the vertebrate lymphatic vasculature. Development2013; 140(9):1857–70.
5.
Hernández-HernándezOTCamacho-ArroyoI. Regulation of gene expression by progesterone in cancer cells: Effects on cyclin D1, EGFR and VEGF. Mini Rev Med Chem2013; 13(5):635–42.
6.
FischerAWuSHoALLacoutureME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: A systematic review of literature and metaanalysis. Invest New Drugs2013; 31(3):787–97.
7.
LeeKSKimSRParkSJ. Mast Cells Can Mediate Vascular Permeability through Regulation of the PI3K–HIF-1α–VEGF Axis. Am J Respir Crit Car Medi2008; 178:787–97.
8.
SolingenCVBijkerkRde BoerHCRabelinkTJVan ZonneveldAJ. The role of microRNA-126 in vascular homeostasis. Curr Vasc Pharmacol2013; Epub ahead of print.
9.
RabquerBJKochAE. Angiogenesis and vasculopathy in systemic sclerosis: Evolving concepts. Curr Rheumatol Rep2012; 14(1):56–63.
10.
KirtonJPXuQ. Endothelial precursors in vascular repair. Microvasc Res2010; 79(3):193–9.
11.
YamauchiHCristofanilliMNakamuraSHortobagyiGNUenoNT. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol2009; 6(7):387–94.
12.
GuiducciSDistlerODistlerJHMatucci-CerinicM. Mechanisms of vascular damage in SSc—implications for vascular treatment strategies. Rheumatology (Oxford)2008; 47(S):v18–20.
13.
BoesigerJTsaiMMaurerMYamaguchiMBrownLFClaffeyKPDvorakHFGalliSJ. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fce receptor I expression. J Exp Med1998; 188:1135–45.
AlbiniATosettiFLiVWNoonanDMLiWW. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol2012; 9(9):498–509.
16.
HaoNBLüMHFanYHCaoYLZhangZRYangSM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol2012; 2012:948098.
17.
GrutzkauAKruger-KrasagakesSBaumeisterHSchwarzCKogelHWelkerPLippertUHenzBMMollerA. Synthesis, storage and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: Implications for the biological significanceof VEGF206Mol Biol Cell1998;9:875–84.
18.
LubkowskaADolegowskaBBanfiG. Growth factor content in PRP and their applicability in medicine. J Biol Regul Homeost Agents2012; 26(S):3S–22S.
19.
HartwigFPNedelFCollaresTVTarquinioSBNörJEDemarcoFF. Telomeres and tissue engineering: The potential roles of TERT in VEGF-mediated angiogenesis. Stem Cell Rev2012; 8(4): 1275–81.
20.
BianchiEScarinciFGrandeC. Immunohistochemical profile of VEGF, TGF-β and PGE2 in human pterygium and normal conjunctiva: Experimental study and review of the literature. Int J Immunopathol Pharmacol2012; 25(3):607–15.
21.
ChrousosGP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med1995; 332:1351–62.
MakindeTAgrawalDK. Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. J Cell Mol Med2008; 12(3):810–28.
24.
MakindeTAgrawalDK. Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. J Cell Mol Med2008; 12(3):810–28.
25.
DethelfsenSMMatsumuraNZetterBR. Mast cell accumulation at sites of murine tumor implantation: Implications for angiogenesis and tumor metastasis. Invasion Metastasis1994; 14:395–408.
ArmstrongAWVoylesSVArmstrongEJFullerENRutledgeJC. Angiogenesis and oxidative stress: Common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci2011; 63(1): 1–9.
28.
ImoukhuedePIDokunAOAnnexBHPopelAS. Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2013; 304(8):H1085–93.
29.
HagAMPedersenSFChristoffersenCBinderupTJensenMMJørgensenJTSkovgaardDRipaRSKjaerA. (18)F-FDG PET imaging of murine atherosclerosis: Association with gene expression of key molecular markers. PLoS One2012; 7(11):e50908.
30.
SharmaBAlbigAR. Matrix Gla protein reinforces angiogenic resolution. Microvasc Res2013; 85:24–33.
31.
NienartowiczASobanice-LotowskaMEJarocka-CyrtaELemancewiczD. Mast cells in neoangiogenesis. Med Sci Monit2006; 12: RA53–RA56.
32.
SasahiraTUedaNKuriharaMMatsushimaSOhmoriHFujiiKBhawalUKYamamotoKKiritaTKuniyasuH. Tropomyosin receptor kinases B and C are tumor progressive and metastatic marker in colorectal carcinoma. Hum Pathol. 2013; 44(6): 1098–106.
33.
SpinettiGFortunatoOCaporaliA. MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia. Circ Res2013; 112(2):335–46.
34.
IndraccoloS. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors. Adv Exp Med Biol2013; 734:37–52.
35.
AndreouKRajendranRKrstic-DemonacosMDemonacosC. Regulation of CXCR4 gene expression in breast cancer cells under diverse stress conditions. Int J Oncol. 2012; 41(6):2253–9.
36.
HuangSYangNLiuYHuLZhaoJGaoJLiYLiCZhangXHuangT. Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling. Nutr Res2012; 32(7):530–6.
37.
OzdemirO. Mast cells and the tumor-associated neoangiogenesis. Med Sci Monit2006; 12:LE9–LE11.
38.
AnselmiFOrlandiniMRocchigianiMDe ClementeCSalamehALentucciCOlivieroSGalvagniF. c-ABL modulates MAP kinases activation downstream of VEGFR-2 signaling by direct phosphorylation of the adaptor proteins GRB2 and NCK1. Angiogenesis2012; 15(2):187–97.
39.
MartiniDMonteMDRistoriCCupistiEMeiSFioriniPFilippiLBagnoliP. Antiangiogenic effects of β2 -adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem2011; 119(6):1317–29.
40.
TaralloVTudiscoLDe FalcoS. A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism. Am J Cancer Res2011; 1(2):265–74.
41.
HoangMVNagyJASengerDR. Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: Mechanistic similarities with angiopoietin-1. Blood2011; 117(5): 1751–60.
42.
MecoDServideiTZannoniGFMartinelliEPriscoMGde WaureCRiccardiR. Dual inhibitor AEE788 reduces tumor growth in preclinical models of medulloblastoma. Transl Oncol2010; 3(5):326–35.
43.
de BoerAGBreimerDD. Cytokines and blood-brain barrier permeability. Prog Brain Res1998; 115:425–51.
44.
RanieriGPantaleoMPiccinnoMRoncettiMMutinatiMMarechIPatrunoRRizzoASciorsciRL. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative review. Crit Rev Oncol Hematol2013; doi:pii: S1040-8428(13)00103-0.
45.
HwangSHWeckslerATZhangGMorisseauCNguyenLVFuSHHammockBD. Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. Bioorg Med Chem Lett2013; 23(13):3732–7.
46.
XiLZhangJQLiuZCZhangJHYanJFJinYLinJ. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: Synthesis, biological evaluation and molecular docking. Org Biomol Chem2013; 11(26):4367–78.
47.
NiwakawaMYamaguchiROnozawaYYasuiHTakuKNaitoTAkinagaSBokuNYamamotoN. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors. Cancer Sci2013; Epub ahead of print.
48.
YamagishiNTeshima-KondoSMasudaKNishidaKKuwanoYDangDTDangLHNikawaTRokutanK. Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells. BMC Cancer2013; 13:229.
49.
DabbousMKWalkerRHaneyLCarterLMNicolsonGLWoolleyDE. Mast cells and matrix degradation at sites of tumor invasion in rat mammary adenocarinoma. Br J Cancer1986; 54:459–65.
50.
WuYZhuZ. Vascular endothelial growth factor receptor 1, a therapeutic target in cancer, inflammation and other disorders. Curr Med Chem2009; 16(22):2890–8.
51.
BandMShamsIJoelAAviviA. Cloning and in vivo expression of vascular endothelial growth factor receptor 2 (Flk1) in the naturally hypoxia-tolerant subterranean mole rat. FASEB J2008; 22(1):105–12.
52.
ZacharyI. VEGF signalling: Integration and multitasking in endothelial cell biology. Biochem Soc Trans2003; 31(Pt 6):1171–7.
53.
GoldLIRahmanMBlechmanKM. Overview of the role for calreticulin in the enhancement of wound healing through multiple biological effects. J Investig Dermatol Symp Proc2006; 11(1):57–65.
54.
HebdaJKLeclairHMAzziSRousselCScottMGBidèreNGavardJ. The C-terminus region of β-arrestin1 modulates VE-cadherin expression and endothelial cell permeability. Cell Commun Signal2013; 11(1):37.
55.
GalliSJNakaeSTsaiM. Mast cells in the development of adaptive immune responses. Nat Immunol2005; 6:135–42.
56.
EtulainJFondevilaCNegrottoSSchattnerM. Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin. Br J Pharmacol2013; Epub ahead of print.
57.
YanCWangCDongMLiuSQiCZhaoY. RNA interference-mediated silencing of VEGF and bFGF suppresses endostatin secretion in pancreatic carcinoma cells. Oncol Lett2013; 5(3):1031–35.
58.
JiangZYQinSKYinXJChenYLZhuL. Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model. Exp Ther Med2012; 4(2):277–284.
59.
HuWXiaLJChenFHWuFRTangJChenCZJiangSChenHH. Recombinant human endostatin inhibits adjuvant arthritis by down-regulating VEGF expression and suppression of TNF-α, IL-1β production. Inflamm Res2012; 61(8):827–35.
60.
StarkeyJRCrowlePKTaubenbergerS. Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer1988; 42:48–52.
61.
GriffioenAWvan der SchaftDWBarendsz-JansonAFCoxABoudierHA StruijkerHillenHFMayoKH. Anginex, a designed peptide that inhibits angiogenesis. Biochem J2001; 354(Pt 2):233–42.
62.
PratsACVan den BergheLRayssacA. CXCL4L1-fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis. Microvasc Res2013; Epub ahead of print.
63.
YariKAfzaliSMozafariHMansouriKMostafaieA. Molecular cloning, expression and purification of recombinant soluble mouse endostatin as an antiangiogenic protein in Escherichia coli. Mol Biol Rep2013; 40(2):1027–33.
64.
YokoyamaYRamakrishnanS. Binding of endostatin to human ovarian cancer cells inhibits cell attachment. Int J Cancer2007; 121(11):2402–9.
65.
StoverDGBierieBMosesHL. A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem2007; 101:851–61.
66.
LeeWYWangCJLinTYHsiaoCLLuoCW. CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor. Am J Physiol Endocrinol Metab2013; 304(1):E32–40.
RodewaldHRDessingMDvorakAMGalliSJ. Identification of a committed precursor for the mast cell lineage. Science1996; 271:818–22.
69.
De GrootJReardonDABatchelorTT. Antiangiogenic therapy for glioblastoma. Am Soc Clin Oncol Educ Book2013; 2013:71–78.
70.
JeongSJHanSHKimCOChoiJYKimJM. Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis. Crit Care2013; 17(3):R97. Epub ahead of print.
71.
BradshawMMansfieldAPeikertT. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep2013; 15(3):207–16.
72.
ReubiJCWaserBValeWRivierJ. Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab2003; 88:3312–20.
73.
LinMLChungJGLuYCYangCYChenSS. Rhein inhibits invasion and migration of human nasopharyngeal carcinoma cells in vitro by down-regulation of matrix metalloproteinases-9 and vascular endothelial growth factor. Oral Oncol. 2009; 45(6):531–7.
74.
KimIRyuYSKwakHJAhnSYOhJLYancopoulosGDGaleNWKohGY. EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin l-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB J2002; 16(9): 1126–8.
75.
ChangLHPanSLLaiCYTsaiACTengCM. Activated PAR-2 Regulates Pancreatic Cancer Progression through ILK/HIF-α-Induced TGF-α Expression and MEK/VEGF-A-Mediated Angiogenesis. Am J Pathol2013; Epub ahead of print.
76.
PopivanovaBKKitamuraKWuY. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest2008; 118:560–70.
77.
TawfikAAl-ShabraweyMRoonPSonneSCovarJAMatragoonSGanapathyPSAthertonSSEl-RemessyAGanapathyVSmithSB. Alterations of retinal vasculature in cystathionine-Beta-synthase mutant mice, a model of hyperhomocysteinemia. Invest Ophthalmol Vis Sci2013; 54(2):939–49.
78.
LiuHZhangWXuZCaldwellRWCaldwellRBBrooksSE. Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway. Invest Ophthalmol Vis Sci2013; 54(2):918–31.
79.
Dal MonteMFilippiLBagnoliP. Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants. Naunyn Schmiedebergs Arch Pharmacol2013; 386(4):269–78.
80.
ItoTKomeimaKYasumaTEnomotoAAsaiNAsaiMIwaseSTakahashiMTerasakiH. Girdin and its phosphorylation dynamically regulate neonatal vascular development and pathological neovascularization in the retina. Am J Pathol2013; 182(2):586–96.
81.
MillerJWLe CouterJStraussECFerraraN. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology2013; 120(1):106–14.
82.
EspositoPChandlerNKandere-GrzybowskaKBasuSJacobsonSConnollyRTutorDTheoharidesTC. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther2002; 303:1061–66.
83.
OwenLAHartnettME. Soluble Mediators of Diabetic Macular Edema: The Diagnostic Role of Aqueous VEGF and Cytokine Levels in Diabetic Macular Edema. Curr Diab Rep2013; Epub ahead of print.
84.
LeeWJKangMHSeongMChoHY. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol2012; 96(11):1426–30.
85.
KossMJPfisterMRothweilerFMichaelisMCinatlJSchubertRKochFH. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol2012; 90(2):e98–e103.
86.
SohnHJHanDHKimITOhIKKimKHLeeDYNamDH. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol2011; 152(4):686–94.
87.
della RovereFGranataAFamiliariDD'ArrigoGMondelloBBasileG. Mast cells in invasive ductal breast cancer: Different behavior in high and minimum hormone-receptive cancers. Anticancer Res2007; 27:2465–71.
88.
TerrasiMBazanVCarusoS. Effects of PPARΓ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. J Cell Physiol2013; 228(6):1368–74.
89.
ChenCTDuYYamaguchiHHsuJMKuoHPHortobagyiGNHungMC. Targeting the IKKβ/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol Cancer Ther2012; 11(10):2212–21.
90.
PriceRSCavazosDADe AngelREHurstingSDdeGraffenriedLA. Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer Prostatic Dis2012;15(2):135–43.
91.
TheoharidesTCSinghLKBoucherWPangXLetourneauRWebsterEChrousosG. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. Endocrinology1998; 139:403–13.
92.
ThompsonCAPurushothamanARamaniVCVlodavskyISandersonRD. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem2013; 288(14): 10093–9.
93.
WenJZhaoYLiJWengCCaiJYangKYuanHImperato-McGinleyJZhuYS. Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells. Prostate2013; 73(10):1069–81.
ZhangJYeJMaDLiuNWuHYuSSunXTseWJiC. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/D114 pathway. Carcinogenesis2013; 34(3):667–77.
96.
LangUEBorgwardtS. Molecular mechanisms of depression: Perspectives on new treatment strategies. Cell Physiol Biochem2013; 31(6):761–77.
O'ConnorJPJaysonGC. Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?Clin Cancer Res2012; 18(24):6588–98.
99.
LangUEBorgwardtS. Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies. Cell Physiol Biochem2013; 31(6):761–77.
100.
RibattiD. Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis. Immunol Lett2013; 152(2):83–88.
101.
GyanchandaniRSanoDAlvesMV OrtegaKleinJDKnapickBAOhSMyersJNKimS. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncol2013; Epub ahead of print.
